• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MICRO THERAPEUTICS, INC. DBA EV3 MARATHON; CATHETER, CONTINUOUS FLUSH

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MICRO THERAPEUTICS, INC. DBA EV3 MARATHON; CATHETER, CONTINUOUS FLUSH Back to Search Results
Model Number UNK-NV-MARATHON
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Pulmonary Embolism (1498); Headache (1880); Intracranial Hemorrhage (1891); Perforation of Vessels (2135); Lethargy (2560); Unspecified Nervous System Problem (4426)
Event Date 09/08/2020
Event Type  Injury  
Manufacturer Narrative
This article was previously reported in manufacturer reports # 2029214-2022-00389 and 2029214-2022-00390.Koyanagi m, mosimann pj, nordmeyer h, et al.The transvenous retrograde pressure cooker technique for the curative embolization of high-grade brain arteriovenous malformations.Journal of neurointerventional surgery.2021;13(7):637-641.Doi:10.1136/neurintsurg-2020-016566.If information is provided in the future, a supplemental report will be issued.
 
Event Description
Koyanagi m, mosimann pj, nordmeyer h, et al.The transvenous retrograde pressure cooker technique for the curative embolization of high-grade brain arteriovenous malformations.Journal of neurointerventional surgery.2021;13(7):637-641.Doi:10.1136/neurintsurg-2020-016566 medtronic literature review found a report of patient complications in association with onyx and apollo and marathon catheters.The purpose of this article was to evaluate the cure rate and safety of the transvenous retrograde pressure cooker technique (rpct) using coils and n-butyl-2-cyanoacrylate as a venous plug for embolization of brain arteriovenous malformations (avms).Fifty-one patients (20 women; median age 47 years) were included.An unknown number of the 51 patients were treated using onyx and apollo catheters.Complete obliteration was observed in 49/51 patients.The article does not state any technical issues during use of the onyx or apollo or marathon catheters.  the following intra- or post-procedural outcomes were noted: postoperative intracranial hemorrhage occurred in three patients: the first was a patient with a ruptured dorsal midbrain avm that initially presented with ventricular bleeding.After an uneventful rpct and complete exclusion, the patient developed pulmonary embolism that was anticoagulated, followed by headaches and somnolence on the following day.A ct revealed an intracerebral hematoma in the left thalamus extending to the corona radiata and ventricular system, possibly precipitated by anticoagulation. the second bleed occurred in a patient with a right-sided basal ganglial avm who initially presented with putaminal hemorrhage and left hemiparesis.Venous perforation occurred during catheterization of a long and tortuous frontobasal vein.Nonetheless, prompt curative embolization could be achieved, including perforation site.Minimal subarachnoid contrast extravasation was observed on cone-beam ct, which remained clinically uneventful.The third happened in a hemiparetic patient with a four-time ruptured left-sided basal ganglial avm previously treated twice by stereotactic radiosurgery.Despite an uneventful curative rpct, a parenchymal hematoma with intraventricular extension requiring surgical evacuation developed 24 hours later.Recovery to his pre-operative status (mrs 4) was observed at 30 days.-five experienced at least 1-point mrs worsening at 30 days.At 1 year, two improved and regainedtheir pre-interventional condition (5.9% transient morbidity).One with a pre-mrs of 3 gradually decreased to 4 at 30 days and 5 at 1 year, despite any treatment-related ischemic or hemorrhagic changes.Clinical worsening was attributed to wasting syndrome.One with a pre-mrs of 1 increased to 2 at 30 days and 1 year and thus categorized as minor permanent morbidity.As a result, one major treatment-related complication (2%) was observed in our series.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
MARATHON
Type of Device
CATHETER, CONTINUOUS FLUSH
Manufacturer (Section D)
MICRO THERAPEUTICS, INC. DBA EV3
9775 toledo way
irvine CA 92618
Manufacturer (Section G)
MICRO THERAPEUTICS, INC. DBA EV3
9775 toledo way
irvine CA 92618
Manufacturer Contact
glen belmer
9775 toledo way
irvine, CA 92618
6122713209
MDR Report Key14781784
MDR Text Key294660082
Report Number2029214-2022-01044
Device Sequence Number1
Product Code KRA
Combination Product (y/n)N
Reporter Country CodeGM
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Literature,Health Professional
Reporter Occupation Physician
Type of Report Initial
Report Date 06/22/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberUNK-NV-MARATHON
Device Catalogue NumberUNK-NV-MARATHON
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 06/20/2022
Initial Date FDA Received06/22/2022
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Disability; Required Intervention;
Patient Age47 YR
Patient SexMale
-
-